Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (422)	7/27/2007 2:18:45 PM
From: tuck	Read Replies (1) \| Respond to of 447

OSI actually manages to offload the Eyetech stuff --or at least some of it -- but they are not saying how low a price they sold it for . . . >>12:03PM OSI Pharm announces agreement to divest anti-platelet derived growth factor program (OSIP) 31.13 -0.39 : Co announces its subsidiary, Eyetech, has entered into an agreement with Ophthotech Corp to divest its anti-platelet derived growth factor aptamer program. Under the terms of the agreement, the co will transfer to Ophthotech all rights in the P.D.G.F aptamer program, including rights to its pre-clinical compound E10030, in exchange for an upfront cash payment, an equity interest in Ophthotech and potential future milestones and royalties. Financial terms of the agreement have not been disclosed.<< From Briefing.com Cheers, Tuck